|drug823||Cognitive Stimulation Wiki||0.71|
|D019965||Neurocognitive Disorders NIH||0.71|
|D060825||Cognitive Dysfunction NIH||0.20|
There are 2 clinical trials
This study project includes a single-arm phase 2 study and a parallel observational cohort study, enrolling patients with COVID-19 pneumonia.
Description: 1-month mortality is defined as the ratio of patients who will alive after 1month from study start out of those registered at baselineMeasure: One-month mortality rate Time: up to 1 month
Description: IL-6 levels will be assessed using commercial ELISA method.Measure: Interleukin-6 level Time: baseline, during treatment (cycle 1 and 2 every 12 hours) up to 1 month
Description: Lymphocyte count assessed by routinely used determination of blood countMeasure: Lymphocyte count Time: baseline, during treatment (cycle 1 and 2 every 12 hours) up to 1 month
Description: CRP is assessed by routinely used determination of CRPMeasure: CRP (C-reactive protein) level Time: baseline, during treatment (cycle 1 and 2 every 12 hours) up to 1 month
Description: calculated from arterial blood gas analyses (values from 300 to 100)Measure: PaO2 (partial pressure of oxygen) / FiO2 (fraction of inspired oxygen, FiO2) ratio (or P/F ratio) Time: baseline, during treatment (cycle 1 and 2 every 12 hours) up to 1 month
Description: It evaluates 6 variables, each representing an organ system (one for the respiratory, cardiovascular, hepatic, coagulation, renal and neurological systems), and scored from 0 (normal) to 4 (high degree of dysfunction/failure). Thus, the maximum score may range from 0 to 24.Measure: Change of the SOFA (Sequential Organ Failure Assessment) Time: baseline, during treatment (cycle 1 and 2 every 12 hours) up to 1 month
Description: graded according to CTCAE citeria (v5.0)Measure: Number of participants with treatment-related side effects as assessed by Common Terminology Criteria for Adverse Event (CTCAE) version 5.0 Time: during treatment and up to 30 days after the last treatment dose
Description: Thoracic CT scan or Chest XRMeasure: Radiological response Time: at baseline (optional), after seven days and if clinically indicated (up to 1 month)
Description: Days of hospitalizationMeasure: Duration of hospitalization Time: from baseline up to patient's discharge (up to 1 month)
Description: time to invasive mechanical ventilation (if not previously initiated) calculated from baseline to intubationMeasure: Remission of respiratory symptoms Time: up to 1 month
Description: time to definitive extubation calculated from intubation (any time occurred) to extubation in daysMeasure: Remission of respiratory symptoms Time: up to 1 month
Description: time to independence from non-invasive mechanical ventilation calculated in daysMeasure: Remission of respiratory symptoms Time: up to 1 month
Description: time to independence from oxygen therapy in daysMeasure: Remission of respiratory symptoms Time: up to 1 month
Assessment of Efficacy and Safety of Tocilizumab Compared to DefeROxamine, associated with standards treatments in COVID-19 (+) patients, Hospitalized In Intensive care in Tunisia. Multicentric, comparative, randomized study.
Description: Evaluate the mortality rate at 90 days. Evaluate the Intensive Care Unit (ICU) and Hospital Mortality rate at day 90 with date and cause of death (if applicable)Measure: the mortality rate Time: 90 day
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports